Stay updated on Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision: v3.3.2 appears as the site revision tag, replacing v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedThe general government funding notice about operating status was removed; otherwise the study record history content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check49 days agoChange DetectedThe two screenshots show the same Record History table with no new version data or changes to core content. Only minor UI/visual adjustments are evident.SummaryDifference0.1%

- Check71 days agoChange DetectedAdded a government-operating-status notice and a version bump to v3.2.0; removed the previous version label v3.1.0.SummaryDifference10%

- Check78 days agoChange DetectedUpdate: version bumped from v3.0.2 to v3.1.0.SummaryDifference0.2%

- Check92 days agoChange DetectedPage revision updated from v3.0.1 to v3.0.2; the Back to Top element was removed, with no substantive content changes otherwise.SummaryDifference0.6%

Stay in the know with updates to Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.